Following the programs success, tirzepatide was approved by the United States Food and Drug Administration (FDA) in 2022 as a treatment for T2D, at doses up to 15mg/weekly under the brand name Mounjaro [1, 5]
Plasma samples were stored at 70 C until analysis
Bell CJM, Mehta M, Mirza L, Young AH, Beck K
Through these processes, the FDA ensures that oral semaglutide is safe for weight loss and provides significant benefits for individuals struggling with obesity or weight management
I realized there certainly is a better way, and I don't want to undermine conventional allopathic care, but certainly it let me down early on, and that was kind of my trajectory